Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bimalangshu Dey, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Bimalangshu Dey and Steven McAfee.
Bimalangshu Dey
Connection Strength
2.293
Steven McAfee
  1. Hematopoietic Stem-Cell Transplantation in the Resource-Limited Setting: Establishing the First Bone Marrow Transplantation Unit in Bangladesh. J Glob Oncol. 2018 09; 4:1-10.
    View in: PubMed
    Score: 0.173
  2. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 May; 20(5):730-4.
    View in: PubMed
    Score: 0.142
  3. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010 Oct 27; 90(8):905-11.
    View in: PubMed
    Score: 0.113
  4. Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant. 2008 Sep; 42(5):329-35.
    View in: PubMed
    Score: 0.096
  5. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2007 Jul; 40(1):19-27.
    View in: PubMed
    Score: 0.088
  6. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2005 Feb; 128(3):351-9.
    View in: PubMed
    Score: 0.076
  7. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003 May; 9(5):320-9.
    View in: PubMed
    Score: 0.067
  8. Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial. Blood. 2022 Feb 15.
    View in: PubMed
    Score: 0.062
  9. Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients. Oncologist. 2021 11; 26(11):e2082-e2085.
    View in: PubMed
    Score: 0.059
  10. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(11):604-12.
    View in: PubMed
    Score: 0.057
  11. Declining bone marrow harvest quality over 24 years: a single institution experience. Bone Marrow Transplant. 2021 04; 56(4):983-985.
    View in: PubMed
    Score: 0.057
  12. Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2020 12; 55(12):2319-2321.
    View in: PubMed
    Score: 0.055
  13. Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned. Transplantation. 2019 11; 103(11):2366-2372.
    View in: PubMed
    Score: 0.053
  14. Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. Bone Marrow Transplant. 2020 04; 55(4):758-762.
    View in: PubMed
    Score: 0.053
  15. A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
    View in: PubMed
    Score: 0.052
  16. Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. Blood. 2019 07 11; 134(2):211-215.
    View in: PubMed
    Score: 0.051
  17. Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 09; 24(9):1836-1840.
    View in: PubMed
    Score: 0.048
  18. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2018 04 10; 2(7):745-753.
    View in: PubMed
    Score: 0.047
  19. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. Oncologist. 2018 05; 23(5):624-630.
    View in: PubMed
    Score: 0.046
  20. Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
    View in: PubMed
    Score: 0.043
  21. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
    View in: PubMed
    Score: 0.042
  22. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8.
    View in: PubMed
    Score: 0.040
  23. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):80-5.
    View in: PubMed
    Score: 0.039
  24. Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015 Aug; 50(8):1119-24.
    View in: PubMed
    Score: 0.039
  25. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer. 2015 Mar 15; 121(6):951-9.
    View in: PubMed
    Score: 0.037
  26. Patients' and family caregivers' (FC) quality of life (QOL) and mood during hospitalization for hematopoietic stem cell transplantation (HCT). J Clin Oncol. 2014 Nov; 32(31_suppl):160.
    View in: PubMed
    Score: 0.037
  27. Prognostic understanding, quality of life (QOL), and mood in patients undergoing hematopoietic stem cell transplantation (HCT). J Clin Oncol. 2014 Nov; 32(31_suppl):219.
    View in: PubMed
    Score: 0.037
  28. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8.
    View in: PubMed
    Score: 0.037
  29. Engraftment syndrome after allogeneic hematopoietic cell transplantation in adults. Am J Hematol. 2014 Jul; 89(7):698-705.
    View in: PubMed
    Score: 0.036
  30. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80.
    View in: PubMed
    Score: 0.034
  31. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1190-6.
    View in: PubMed
    Score: 0.034
  32. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7.
    View in: PubMed
    Score: 0.033
  33. Expression of a4ß7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplant. 2013 Apr; 48(4):598-603.
    View in: PubMed
    Score: 0.032
  34. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8.
    View in: PubMed
    Score: 0.032
  35. High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leuk Lymphoma. 2011 Jul; 52(7):1363-6.
    View in: PubMed
    Score: 0.029
  36. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation. 2011 Mar 27; 91(6):672-6.
    View in: PubMed
    Score: 0.029
  37. Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1025-31.
    View in: PubMed
    Score: 0.027
  38. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
    View in: PubMed
    Score: 0.027
  39. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1447-54.
    View in: PubMed
    Score: 0.026
  40. High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion. 2009 May; 49(5):995-1002.
    View in: PubMed
    Score: 0.025
  41. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2009 Jan; 43(1):37-42.
    View in: PubMed
    Score: 0.024
  42. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008 Mar; 41(6):523-9.
    View in: PubMed
    Score: 0.023
  43. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol. 2007 Jul; 35(7):1140-52.
    View in: PubMed
    Score: 0.022
  44. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007 Jul; 13(7):838-43.
    View in: PubMed
    Score: 0.022
  45. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan; 13(1):82-9.
    View in: PubMed
    Score: 0.022
  46. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant. 2006 Sep; 6(9):2121-33.
    View in: PubMed
    Score: 0.021
  47. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant. 2003 Jun; 9(6):373-82.
    View in: PubMed
    Score: 0.017
  48. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation. 2003 May 27; 75(10):1748-51.
    View in: PubMed
    Score: 0.017
  49. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation. 2002 Nov 27; 74(10):1405-9.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.